ArticleJTCVS open2026
Outcomes of mitral valve repair in ischemic mitral regurgitation: A two-decade experience.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study objective was to evaluate long-term survival outcomes after mitral valve repair in patients with moderate or moderate-to-severe ischemic mitral regurgitation undergoing concomitant coronary artery bypass grafting. Methods: We retrospectively analyzed 212 consecutive patients who underwent mitral valve repair with restrictive annuloplasty and concomitant coronary artery bypass grafting for ischemic mitral regurgitation and coronary artery disease at a tertiary center between January 2005 and May 2025. Survival at 1, 5, 10, 12, and 20 years was assessed using Kaplan-Meier estimates and Cox proportional hazard models. Differential survivals were compared using hazard ratios for the following variables: age more than 65 years, sex, diabetes, residual postoperative mitral regurgitation, incomplete revascularization, left ventricular ejection fraction less than 40%, left ventricular end-systolic diameter 45 mm or greater, and preoperative renal dysfunction (serum creatinine ≥1.5 mg/dL). Results: Of 212 patients, survival at 1, 5, 10, 12, and 20 years was 97.6%, 94.3%, 88.7%, 87.3%, and 81.1%, respectively. At 12 years, survival was significantly lower in patients with diabetes (82.1% vs 93% in nondiabetic patients; hazard ratio, 2.79 [1.18-6.61], Conclusions: This 2-decade experience shows that mitral valve repair with restrictive annuloplasty combined with coronary artery bypass grafting yields favorable long-term survival in moderate or moderate-to-severe chronic ischemic mitral regurgitation, particularly when residual mitral regurgitation is avoided, revascularization is complete, and preoperative left ventricular end-systolic diameter is less than 45 mm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.